Navigation Links
Launch of Fountain Healthcare Partners, a Life Science Venture Capital Firm
Date:4/29/2008


DUBLIN and NEW YORK, April 29 /PRNewswire/ --

- Announces First Close of EUR75 ($117) Million

- Largest Life Science Venture Capital ("VC") Fund Launched in Ireland

- One of the Largest Emerging Manager VC Funds Raised in the Life

Science Sector Globally

- Headquartered in Dublin, Fountain Will Invest the Majority of its

Capital in Europe With a Primary Focus on Ireland

Fountain Healthcare Partners ("Fountain") today launches and announces the first close of its inaugural fund, Fountain Healthcare Partners I, with EUR75 ($117) million of committed capital.

The fund is the largest dedicated life science (specialty pharmaceuticals, biotechnology, medical devices and diagnostics) venture capital ("VC") firm based in Ireland. It is also one of the largest emerging manager VC funds raised in the life science sector globally in the past 2 years.

Fountain will invest the majority of its capital in Europe and will have a strong emphasis on the life science sector in Ireland. The first close significantly exceeded initial expectations and Fountain is now targeting approximately EUR100 million in commitments at its final close.

Over 90% of the capital invested in the fund was sourced from institutional investors of which 75% are Irish based. Institutional investors include the European Investment Fund, the National Pension Reserve Fund and Enterprise Ireland. A select number of high net worth individual investors also participated. "We have been very pleased with the level and quality of investor participation in the first close. There was clear support for our investment strategy, and we significantly exceeded our original first close target," said Dr Manus Rogan, a founding partner at Fountain.

Fountain is a bi-located fund with a main office in Dublin and a second office in New York. "The purpose of our New York office is to maintain on-the-ground connectivity with the US life-scien
'/>"/>

SOURCE Fountain Healthcare Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch
2. Pathwork(R) Diagnostics Launches Genomics-Based Test For Hard-To-Identify Tumors Through Its CLIA-Certified Laboratory
3. The Lustgarten Foundation for Pancreatic Cancer Research Launches New Public Service Announcement Featuring Last Lecturer Dr. Randy Pausch
4. Hovione Launches New Website
5. International Council on Nanotechnology launches global research needs assessment
6. Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research
7. Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R)
8. Botaneco Announces Launch of Second Generation Oleosome Product
9. Novagali Pharma Announces the Launch of Cationorm(R)
10. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
11. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... 22, 2015 zFlo Motion , a ... announce an exciting product from a new partner. STT-Systems ... over the past 15 years, with offerings in the optical-motion ... 3D IMU system (inertial measurement unit), iSen, is opening eyes ...
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... SAN DIEGO, May 17, 2011 Verenium Corporation (Nasdaq: ... focused on the development and commercialization of high-performance enzymes, ... by MDB Capital Group at the second annual Bright ...  The Bright Lights Conference is the only conference with ...
... Life Technologies Corporation (NASDAQ: LIFE ... of Gibco® Freedom™ Cell Line Development Kits , a ... media and protocols to bring simplicity and flexibility, eliminating up ... drug development.  These kits make it easier and faster to ...
... May 16, 2011 Masimo ... from a new study published in the American ... hemoglobin (SpHb®) monitoring correlates strongly with invasive laboratory hemoglobin ... and critical care setting and may potentially decrease the ...
Cached Biology Technology:Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 2Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 3Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 4Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 2Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 3Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 4Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 5New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 2New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 3New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 4New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 5New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 6
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ...  report to their offering. One major ... With continuous advances in technology, it is important to ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... , PITTSBURGH, Feb. 13, 2014 University of Pittsburgh ... be able to do new tricks., By screening a library ... as a treatment for a rare type of cancer, UPCI ... try if the cancer becomes resistant to standard drug treatment., ...
... Children,s Hospital of Philadelphia (CHOP) have developed a ... encode HLA molecules. The test relies on faster, ... leukocyte antigens (HLAs)--complex, highly variable proteins on cell ... The new test may improve transplantation outcomes through ...
... has been named a Fellow of the American Association ... the field of global change ecology, particularly for pioneering ... Models or forecasts similar to those produced for ... the environment will alter an entire ecosystem in the ...
Cached Biology News:Laboratory detective work points to potential therapy for rare, drug-resistant cancer 2CHOP introduces HLA typing by next-generation sequencing to its clinical services 2CHOP introduces HLA typing by next-generation sequencing to its clinical services 3
... Immunogen: Synthetic peptide derived from the ... mouse dog and orangutang occludin proteins. ... occludin protein. Reactivity: Human (positive ... with rat mouse dog and orangutang ...
...
... protein western blot (WtPAN) is ... specific protein expression in plant ... is included in each blot ... comparison between different western blots. ...
... Water is suitable for use ... by incubating with 0.1% diethylpyrocarbonate ... remove the DEPC.DNase/RNase-Free Distilled WaterDistilled ... in all molecular biology applications. ...
Biology Products: